Overview

• Chief commercial officer Luke Miels, 50, will assume full CEO responsibilities on January 1 after joining GSK in 2017.
• Emma Walmsley will leave the board at year-end and remain employed until her notice period ends on September 30, 2026.
• GSK said the selection followed a rigorous process that considered internal and external candidates.
• Miels is tasked with leading the company’s next phase focused on delivering sales of more than £40 billion by 2031.
• Walmsley’s tenure featured the Haleon demerger and a pivot to specialty medicines and vaccines, with GSK shares down nearly 6% since 2017.